We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-1.62%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.99B
AUM Growth
-$546M
Cap. Flow
-$71.8M
Cap. Flow %
-2.4%
Top 10 Hldgs %
48.59%
Holding
90
New
10
Increased
29
Reduced
22
Closed
16
Avg Time Held Equity + Options
1.3 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
1.2 years
Avg Time Held Equity only
1.3 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
1.2 years

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$131M
2
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$75.7M
3
IGMS icon
IGM Biosciences
IGMS
+$63.5M
4
ALLK icon
Allakos
ALLK
+$51.3M
5
NVRO icon
NEVRO CORP.
NVRO
+$48.5M

Top Sells

Rank Stock Value
1
ARRY icon
Array Biopharma Inc
ARRY
+$405M
2
EHTH icon
eHealth
EHTH
+$76.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$62.6M
4
ELV icon
Elevance Health
ELV
+$51.8M
5
UNH icon
UnitedHealth
UNH
+$34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Miscellaneous 0.93%
3 Energy 0.01%
4 Technology 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BMRN icon
76
BioMarin Pharmaceuticals
BMRN
$10.8B
– –
-97,191
Closed -$8.32M –
EHTH icon
77
eHealth
EHTH
$19.4M
– –
-888,705
Closed -$76.5M –
ELV icon
78
Elevance Health
ELV
$92.9B
– –
-183,500
Closed -$51.8M –
PSNL icon
79
Personalis
PSNL
$1.7B
– –
-400,000
Closed -$10.9M –
SRPT icon
80
Sarepta Therapeutics
SRPT
$1.88B
– –
-412,000
Closed -$62.6M –
TDOC icon
81
Teladoc Health
TDOC
$1.08B
– –
-461,880
Closed -$30.7M –
ONC icon
82
BeOne Medicines Ltd
ONC
$42.3B
– –
-39,900
Closed -$4.95M –
MOR icon
83
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-733,699
Closed -$17.7M –
NVTA
84
DELISTED
Invitae Corporation
NVTA
– –
-375,375
Closed -$8.82M –
JNCE
85
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-254,590
Closed -$1.26M –
GBT
86
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-188,000
Closed -$9.89M –
OXFD
87
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-1,796,477
Closed -$24.7M –
AVDR
88
DELISTED
Avedro, Inc Common Stock
AVDR
– –
-216,200
Closed -$4.25M –
ARRY icon
89
DELISTED
Array Biopharma Inc
ARRY
– –
-8,752,254
Closed -$405M –
1 2 3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2019 Portfolio in Review

As of Q3 2019, Redmile Group held 90 positions worth $2.99B, down 15% from $3.53B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q3 2019 filing shows 10 new, 29 increased, 22 reduced and 16 closed positions. Its largest new stake was Alexion Pharmaceuticals: 1,162,200 shares worth $114M. The largest sale was Array Biopharma Inc, an estimated $405M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Energy.

  • Redmile Group's largest Q3 2019 buy was Alexion Pharmaceuticals: 1,162,200 shares worth $114M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019, an estimated $75.7M increase.
  • Redmile Group's biggest Q3 2019 reduction was UnitedHealth, cutting an estimated $34M.
  • Redmile Group fully exited Array Biopharma Inc in Q3 2019, selling an estimated $405M.
  • Redmile Group's ten largest holdings make up 49% of its $2.99B portfolio in Q3 2019.
  • Redmile Group opened 10 new positions and closed 16 in Q3 2019.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $2.99B.

Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.